Previous 10 | Next 10 |
The following slide deck was published by Pulse Biosciences, Inc. in conjunction with this Read more ...
Pulse Biosciences, Inc.(NASDAQ:PLSE) (“Pulse Biosciences” or the “Company”), a novel medical therapy company bringing to market its proprietary CellFX™ System, today announced the appointment of Mitchell Levinson to its board of directors. In connection wit...
Pulse Biosciences, Inc. (NASDAQ:PLSE), a novel medical therapy company bringing to market its proprietary CellFX™ System, today announced that clinical results from its recently completed Sebaceous Hyperplasia study will be presented at the American Academy of Dermatology (AAD) Annual...
Pulse Biosciences, Inc. (NASDAQ:PLSE), a novel medical therapy company bringing to market its proprietary CellFX™ System today announced the Premarket Notification 510(k) submission to the U.S. Food and Drug Administration (FDA) for its CellFX System. The Company’s FDA filing r...
Pulse Biosciences, Inc. (PLSE) Q4 2018 Earnings Conference Call February 7, 2018 4:30 PM ET Company Participants Darrin Uecker - Chief Executive Officer Brian Dow - Senior Vice President and Chief Financial Officer Ed Ebbers - Executive Vice President and General Manager of Derma...
Pulse Biosciences (NASDAQ: PLSE ): Q4 GAAP EPS of -$0.51. More news on: Pulse Biosciences, Earnings news and commentary, Healthcare stocks news, Read more ...
Pulse Biosciences, Inc. (NASDAQ:PLSE), a novel medical therapy company bringing to market its proprietary CellFX™ System today announced that the Company will report fourth-quarter and full-year 2018 operational highlights and financial results on Thursday, February 7, 2019. Pulse Bio...
Pulse Biosciences, Inc. (NASDAQ:PLSE), a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation (NPS) platform, announced today that the Compensation Committee of the company’s Board of Directors granted non-qualified stock...
Pulse Biosciences, Inc. (PLSE) Q2 2018 Earnings Conference Call July 31, 2018 04:30 pm ET Executives Brian Dow - Senior Vice President and Chief Financial Officer Darrin Uecker - President and Chief Executive Officer Presentation Operator Good day, ladies and gentlemen an...
Pulse Biosciences (NASDAQ: PLSE ): Q2 EPS of -$0.54 More news on: Pulse Biosciences, Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Pulse Biosciences Inc Company Name:
PLSE Stock Symbol:
NASDAQ Market:
Pulse Biosciences Inc Website:
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced it will report financial results for the second quarter 2024 after market close on Monday, August 12, 2024. Company managemen...
2024-07-15 17:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 12.5% to $0.27 on volume of 477,193,667 shares NVIDIA Corporation (NVDA) rose 1.9% to $128.2 on volume of 232,119,115 shares Virpax Pharmaceuticals Inc. (VRPX) rose 92.0% to $1.11 on volume o...